Featured Posts

  

Dispatches From the Crossroads

Rss
Posted by: BIO Ventures for Global Health on 5/4/2012 | 0 Comments
The greatest hurdle for developing countries in leading research and development (R&D) efforts to create lifesaving biomedical tools for patients in their own communities is not scientific expertise, infrastructure, or technological capabilities, but funding. One of the best ways to jumpstart these efforts, improve self-sufficiency and long-term sustainability is for developing world governments to invest R&D programs within their borders.
Categories: Meetings
Posted by: BIO Ventures for Global Health on 5/4/2012 | 0 Comments
 At Forum 2012, 11 of the 32  African Network for Drugs and Diagnostics Innovation (ANDI) Centers of Excellence expressed interested in joining WIPO Re:Search initiative to accelerate their work developing new  drugs, diagnostics, vaccines, medical devices, and traditional medicines for neglected diseases.
Categories: Meetings Partnering
Posted by: BIO Ventures for Global Health on 4/17/2012 | 0 Comments
Manufacturers, researchers, and innovators from emerging markets are spearheading progress in vaccine research and devliery. BVGH CEO Don Joseph shares his insights from last week’s discussions at the World Vaccine Congress about the efforts of Brazil, Russia, India, and China in shaping vaccine technologies, pricing structures, and availability worldwide.
Categories: Meetings News
Posted by: BIO Ventures for Global Health on 3/27/2012 | 0 Comments
We’ve all heard that the average cost of developing just one new drug is estimated at over $1 billion. But what does this really mean for research and development (R&D) for neglected tropical diseases, on which only $3.1 billion was spent in 2010? To find out more, we at BIO Ventures for Global Health – for the first time – identified 348 organizations and uncovered how each is involved in the 374 drugs and vaccines currently in development for neglected diseases.
Posted by: BIO Ventures for Global Health on 3/15/2012 | 0 Comments
Research-driven economies work.  But today, the United States ranks sixth in terms of the proportion of gross domestic product invested in R&D. To keep pace with emerging global powerhouses and to speed economic recovery, the United States — standing at the crossroads of an election — must prioritize health R&D funding. And American voters agree.
Posted by: BIO Ventures for Global Health on 3/12/2012 | 0 Comments
When it comes to global development, success cannot be achieved through developing and investing in projects. Instead, we must develop and invest in people, and we must do this by appealing to people’s interests and harnessing the power of their diverse skills. About 64% of people with mobile phones live in the developing world, illustrating how mobile technology is one way to reach and empower people to build healthy, long lives.
Posted by: BIO Ventures for Global Health on 2/29/2012 | 0 Comments
The message at the Global Health Technologies Coalition’s recent Capitol Hill briefing was clear: millions of lives have been saved across the globe because of American innovation in global health. But the impact of global health is even greater than that. It spurs innovation to create new tools that fight against neglected tropical diseases and avert pandemics. It helps Americans travelling abroad and soldiers in the U.S. military. And -- what is likely most important to many Americans -- investing in research leads to the creation of new jobs as well as diplomacy advancements.
Posted by: BIO Ventures for Global Health on 2/1/2012 | 0 Comments
New CEO Don Joseph has just returned from London, where the Gates Foundation, in conjunction with the World Health Organization and 13 of the world’s largest pharmaceutical companies, announced a new effort to end or control ten neglected tropical diseases. As we work together to achieve this goal, he writes, it is important to acknowledge that poverty and the neglect of populations create the environment that allows these diseases to thrive.
Posted by: BIO Ventures for Global Health on 1/6/2012 | 0 Comments
Diagnostics play a key role in our understanding and management of diseases   -- they can be used to evaluate and map disease prevalence, guide patient care, evaluate treatment efficacy, and measure the impact of control and prevention interventions. In order to better understand diagnostic needs and diagnostics currently in development for neglected diseases, we have expanded the Global Health Primer to include diagnostic development pipelines.
Posted by: BIO Ventures for Global Health on 12/9/2011 | 0 Comments
Inequality. Patients’ needs. Progress (and lack of). Imbalance. Patents and the IP system. Sustainability. Access. Innovation. These are just some of the themes I heard addressed late last week at DNDi's annual partners’ meeting. These are not new themes in global health, yet they stimulated quite an array of passion and discussion at the DNDi sessions. I came away impressed by not only the passion but the commitment of the participants in addressing the issues.
Categories: Meetings
1 2 3 4 5 6 7 8 9  Go to Page:

  

Recent Comments

by Chad on Coffee Break
"It is really sad that third-world countries suffer so much from an assortment of diseases and we tend to live without worrying about it. Only in a perfect world could the public and privates sectors work together as a "super-power" to recognize and fix these problems, but as of the current economic conditions it seems to be fading even more. Honestly, this is such a sad moment for everyone!" Read more »

by Yina on A Shifting Paradigm?
"As a long time agent of change in the Healthcare space, I have seen the under uliaizttion of technology. It is not bleeding edge' technology that causes me concern but the more mature ones that have been poorly driven and implemented. Much of this can be attributed to the Change Management plan. We fail to fully vet pilot sites, we jam data and processing into the pipe without taking avantage of future implementations, we include the directly affected stakeholders long after implementation starts and we don't analyze the impact on systems and layered products needed for success. The resourcing and uliaizttion of analysts, technical tactitions and workflow specialtists is arduous and expensive (and often considered unnecessary). However, the reengineering of applications and lost hours due to disruption at the user end needs to be added to the cost algorithm. After all even a medium sized system implementation failure creates grief for anyone else trying to affect change in the same user environment." Read more »

by Christian on Crossing the Valley of Death
"If the NIH could find a way to get the CAN funded then we could get some more research and development on the way. Congress just needs to approve the funding for this project. Thanks..." Read more »